Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With fears of a global recession rising, it’s natural that investors have turned their back on growth-intensive names. However, this backdrop has also yielded compelling undervalued biotech stocks to buy. While very ...
The recent Japan approval of Voxzogo for achondroplasia would generate a leaping sales growth in the coming quarters. BioMarin is also expanding Voxzogo's label for younger kids afflicted by achondroplasia. The long-term safety/efficacy data for valoctocogene signifies its upcomin...
BioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 20, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Je...
Bear markets are certainly painful, but they help crystallize new market cycles, correct imbalances and force investors to finally accept that the old bull market is truly over. We continued to refine our positioning, adapting a more defensive posture by adding to health care and util...
Equities reeled in the second quarter as persistent price pressures, global supply chain disruptions and rising recession risks soured sentiment on a post-pandemic recovery looking too big for its britches. The health care, consumer staples and utilities sectors showed their character...
The Strategy underperformed during another difficult quarter for growth stocks, with weakness centered among several COVID-19 beneficiaries that are seeing tough comparisons, rising input costs or both. Positioning moves during the quarter, which included additions in health care and ...
Cantor Fitzgerald has initiated biotechs Vertex Pharmaceuticals ( NASDAQ: VRTX ) and BioMarin ( NASDAQ: BMRN ) Pharmaceutical with overweight ratings on growth prospects. The firm has a $365 price target for Vertex ( VRTX ) (~26% upside based on Tuesday's close) ...
BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Including 4 Oral and 2 Poster Presentations PR Newswire Commitment to Advanci...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
On Friday, BioMarin Pharmaceutical received a positive CHMP opinion in Europe for ValRox for Hemophilia type A treatment. According to the last report, the core portfolio looks solid. Vozxogo remains the main driver of revenue growth this year. If approved in Europe, the start...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...